ImmunityBio Pipeline

DISEASE
INVESTIGATIONAL THERAPEUTICS
TRIAL SITES/COLLABORATORS
PHASE

* Investigator-sponsored studies

Anktiva® (N-803) is an interleukin-15 superagonist fusion protein that is designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells and (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Both agents are in late-stage clinical development by ImmunityBio, which has exclusive, worldwide rights to the agents. Pembrolizumab, sold under the brand KEYTRUDA®, is an FDA-approved immune checkpoint inhibitor marketed by Merck.
QUILT stands for QUantum Integrative Lifelong Trial.

How Can ImmunityBio Help You?

Solutions for Patients

Many cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

The broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

Disease
Bladder Cancer
QUILT-3.032
BCG Unresponsive NMIBC Carcinoma In-Situ & Papillary
Investigational Therapeutics
ANKTIVA + BCG
Trial Sites/Collaborators
32 study locations (see clinicaltrials.gov for details)
Phase
ACCEPTED
Disease
Bladder Cancer
QUILT-2.005
BCG Naïve NMIBC
Investigational Therapeutics
ANKTIVA + BCG
Trial Sites/Collaborators
24 study locations (see clinicaltrials.gov for details)
Phase
Phase 2
Disease
Lung Cancer
QUILT-3.055
Non-Small Cell Lung Cancer
Investigational Therapeutics
ANKTIVA
Trial Sites/Collaborators
31 study locations (see clinicaltrials.gov for details)
Phase
Phase 2
Disease
Colorectal/Lynch Syndrome
QUILT-5.015
Lynch Syndrome (NCI)
Investigational Therapeutics
ANKTIVA + Tri-Ad5 vaccines
Trial Sites/Collaborators
National Cancer Institute (see clinicaltrials.gov for details)
Phase
Phase 2
Disease
Ovarian Cancer
ResQ-209
Planned – Platinum-Resistant Ovarian Cancer
Investigational Therapeutics
ANKTIVA + M-ceNK
Trial Sites/Collaborators
Details to be announced
Phase
Phase 2
Disease
Acute Myeloid Leukemia (AML)
QUILT-102
Acute Myeloid Leukemia
Investigational Therapeutics
ANKTIVA + M-ceNK
Trial Sites/Collaborators
Details to be announced
Phase
Phase 2
Disease
HPV
QUILT-3.100
HPV+ / HPV- 2nd Line Head & Neck Cancer
Investigational Therapeutics
ANKTIVA + Ad5 HPV
Trial Sites/Collaborators
Chan Soon-Shiong Institute for Medicine (El Segundo, CA)
Phase
Phase 1
Disease
Glioblastoma
QUILT-3.078
Recurrent GBM or Progressive GBM
Investigational Therapeutics
ANKTIVA + bevacizumab + PD-L1 t-haNK
Trial Sites/Collaborators
Details to be announced
Phase
Phase 2
Disease
Advanced Solid Tumors
QUILT-3.076
Locally Advanced or Metastatic Solid Tumors
Investigational Therapeutics
ANKTIVA + M-ceNK
Trial Sites/Collaborators
Chan Soon-Shiong Institute for Medicine (El Segundo, CA)
Phase
Phase 1
Disease
Non-Hodgkin Lymphoma
QUILT-3.092
Relapses/Refractory Non-Hodgkin Lymphoma
Investigational Therapeutics
ANKTIVA + CD19 t-haNK
Trial Sites/Collaborators
Hoag Memorial Presbyterian Hospital (Newport Beach, CA)
Phase
Phase 1
Disease
HIV
AIDS Clinical Trials Group (ACTG) / National Institute of Allergy and Infectious Diseases (NIAID): HIV Cure Study*
Investigational Therapeutics
ANKTIVA
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 1
Disease
HIV
Rockefeller University: N-803 +/- 2 bNABs*
Investigational Therapeutics
N-803
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 1
Disease
HIV
Thailand Trial: N-803 in Acute HIV Infection*
Investigational Therapeutics
ANKTIVA
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 2
Disease
HIV
NIAID / University of Minnesota: Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease*
Investigational Therapeutics
ANKTIVA
Trial Sites/Collaborators
See clinicaltrials.gov for details.
Phase
Phase 1
Older Posts
Newer Posts
Sort by:
or